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Background: Four-dimensional flow cardiac magnetic resonance (4D flow CMR) is
an emerging non-invasive imaging technology that can be used to quantify mitral
regurgitation (MR) volume. Current methods of quantification have demonstrated
limitations in accurate analysis, particularly in difficult cases such as complex congenital
heart disease. 4D flow CMR methods aim to circumvent these limitations and allow
accurate quantification of MR volume even in complex cases. This systematic review
aims to summarize the available literature on 4D flow CMR MR quantification methods
and examine their ability to accurately classify MR severity.
Methods: Structured searches were carried out on Medline and EMBASE in
December 2018 to identify suitable research outcome studies. The titles and abstracts
were screened for relevance, with a third adjudicator utilized when study suitability
was uncertain.
Results: Seven studies met the eligibility criteria and were included in the systematic
review. The most widely used 4D flowMRI method was retrospective valve tracking (RVT)
which was examined in five papers. The key finding of these papers was that RVT is a
reliable and accurate method of regurgitant volume quantification.
Conclusions: MR quantification through 4D flow MRI is both feasible and accurate.
The evidence gathered suggests that for MR assessment, 4D flow MRI is potentially
as accurate and reliable to echocardiography and may be complementary to this
technique. Further work on MR quantification 4D flow image analysis is needed to
determine the most accurate analysis technique and to demonstrate 4D flow MRI as a
predictor of clinical outcome.
PROSPERO Registration Number: CRD42019122837,
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019122837
Keywords: mitral regurgitation, 4D flow CMR, 4D flow MRI, phase contrast, echocardiography, retrospective-
valve-tracking
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INTRODUCTION
Mitral regurgitation (MR) is a serious disease of the mitral valve
where blood is allowed to flow from the left ventricle to the
left atrium during systole. Primary MR is caused by a defect
in at least one aspect of the valve apparatus (e.g., mitral valve
leaflet prolapse), whereas secondary MR is a consequence of
other cardiac disease involving the myocardium (e.g., dilated
cardiomyopathy, myocardial infarction) (1). MR is the second
most common valvular condition and is particularly prevalent in
elderly populations; affecting ∼9% of over 75 s (2). Patients with
MR can live formany years without symptoms and then suddenly
decompensate with acute heart failure. Mild or moderate MR
is often conservatively managed. Severe MR is most commonly
treated through surgical repair or replacement of the valve,
although transcatheter intervention techniques are becoming
more frequent (3). The clinical management of MR is based
on many factors including left ventricular size, left ventricular
function and patient symptoms. Current ESC guidelines place
emphasis on the left ventricular ejection fraction (LVEF) and
left ventricular end-diastolic volume (LVEDV) as indicators for
surgery. A LVEF ≤ 60% or LVESD ≥ 45mm are triggers for
surgery in asymptomatic patients. In addition, surgery should be
considered in patients with atrial fibrillation secondary to MR or
pulmonary hypertension. Patient assessment can be made more
difficult by confounding symptoms from commonly associated
diseases or the lack of symptoms even in cases of severe MR
(1, 4, 5). The timing of intervention is often reliant on the
accurate quantification of MR severity; this is crucial to prevent
increased morbidity and mortality in this patient group. Larger
regurgitant volumes have a strong correlation with increasing
mortality, no matter the background pathophysiology (3, 6). It
is therefore important to accurately and precisely quantify MR to
guide clinical decisions.
In routine clinical practice, echocardiography is the standard
assessment tool for MR. However, a limited number of
recent studies have shown that cardiac magnetic resonance
(CMR) to be more accurate when quantifying organic MR
and superior at predicting clinical outcomes when compared
to echocardiography. CMR is the reference imaging modality
for the assessment of left ventricular volumes and ejection
fractions. In addition, it allows clinicians to make an assessment
of the mitral valve morphology and classify MR as primary
or secondary. The addition of late gadolinium enhancement
to standard MRI protocol enables the evaluation of localized
myocardial fibrosis which can be a result of chronic MR. The
extent of fibrosis has been shown to independently predict
outcomes (7). Therefore, CMR is a versatile non-invasive tool
that allows comprehensive multi-parametric assessment of MR
and its etiology (8).
MR can be quantified either directly or indirectly by both
CMR and echocardiography. Both indirect methods calculate the
difference between left ventricular stroke volume (LVSV) and
aortic forward volume (AoPC). This is the current standard,
and most widely used, method of CMR and flow quantification
can be obtained through phase contrast (PC) velocity encoded
imaging. This technique enables the quantification of regurgitant
volume without the consideration of jet number or eccentricity.
Alternative methods of quantification can be performed by both
proximal isovelocity surface area (PISA) by echocardiography
(an indirect method) or by 4-dimensional (4D) flow CMR (a
direct method).
Despite the promise of CMR imaging technique there
are several limitations that prevent clinical application in all
cases. Current CMR MR quantification methods involve two
separate types of acquisition and segmentation, which can
introduce significant bias and lower limits of agreements between
two assessments.
Researchers aiming to address these problems with current
CMR methods have shown significant interest in novel 4-
dimensional (4D) flow imaging techniques. 4D flowMRI involves
PC acquisition with velocity encoding in three-directions
which is also three-dimensional and time-resolved (the fourth
dimension; Figure 1). This allows the dynamic visualization of
flow in multiple orientations retrospectively. The aim of this
systematic review is to methodically summarize 4D flow CMR
MR quantification methods and investigate the robustness of
these methods in the published literature.
METHODS
Systematic Review Registration
At inception, this systematic review was prospectively registered
(CRD42019122837) with the international prospective register
of systematic review (PROSPERO), which is an international
database of prospectively registered systematic reviews in health,
where there is a health related outcome.
Eligibility Criteria
Studies which used 4D flow CMR quantification for the
assessment of MR were included. We limited our search to peer-
reviewed journals, medicine, and human participants. Studies
with fewer than 10 patients or those not published in English
were excluded.
Search Strategy
The literature search was done on the Scopus database. Scopus
is able to undertake 100% search coverage on Medline and
EMBASE (9). The search strategy included: mitral regurgitation
3D velocity CMR (2 results); mitral regurgitation 4D flow MRI
(6 results); mitral regurgitation retrospective valve tracking (4
results). All searches were combined, and duplicates removed.
The search was carried out on 27/11/2018. The flow diagram
below demonstrates the literature search based on the preferred
reporting items for systematic reviews and meta-analyses
(PRISMA; Figure 2).
Study Selection
PRISMA guidelines were used for study identification, screening
and inclusion. Review of the proposed papers was conducted
by PG (10-years of cardiology experience) and BF (3-years as a
medical student). If there was disagreement, a third reviewer, GA
(6-years of cardiology experience), was involved as a deciding
vote. To identify any papers missed by the Scopus database, an
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FIGURE 1 | For whole heart 4D flow acquisition, the field of view is planned to cover all chambers of the heart. The bigger the FOV, the longer will be the acquisition
and more data will be acquired. Focused studies can be done to save time and circumvent acquisition issues like higher heart rate. Separate three-directional,
cross-sectional phase contrast velocity encoded data is acquired throughout the cardiac cycle (30 phases). This is then reconstructed into one cross-sectional
velocity data in software packages for analysis. FOV, field of view; FH, foot head direction; RL, right left direction; AP. Anterior posterior direction; 3D,
three-dimensional; 4D, four-dimensional (fourth dimension: time).
independent search was carried out with the above search terms
on PubMed. After a comprehensive search of the referenced
papers, no other relevant papers were identified.
RESULTS
After a comprehensive review of the content, 7 research outcome
studies were identified (6 from Scopus and 1 from PubMed) and
included in the systematic review process (Table 1). Papers were
excluded for the following reasons: not performed in humans (1),
focused on congenital heart disease (1), were review papers (2), or
had insufficient patient numbers (2). All 7 papers were electronic
sources available online. A summary of these papers can be found
in Table 1.
In a 2008 paper, Westenberg et al. directly compared 2D PC
MRI to 4D flow CMR in order to validate this technique in the
quantification of regurgitation volume. Ten healthy volunteers
and 20 patients with either MR, tricuspid regurgitation or both
were recruited. The 2DPCMRI overestimatedmitral flow by 15%
in both healthy and regurgitation patients. This was also seen in
this group’s future work (13) where 4D CMR was systematically
lower than 2D MRI when assessing transmitral flow rate. 4D
imaging did not overestimate the flow as it was able to adapt to
heart motion and retrospectively track the valve throughout the
cardiac cycle (Figure 3).
Brandts et al. (13), compared 4D flow CMR with RVT and
2D TTE Doppler echocardiography for assessing left ventricular
filling patterns and calculating regurgitation fractions. They
found excellent agreement between the two modalities (k-
agreement= 0.91).
Marsan et al. (11), directly compared 4D flow CMR
with real-time 3D echocardiography (RT3DE) for quantifying
MR. This study included 64 patients with functional MR.
Regurgitant volume had little difference between 3D TTE
technique vs. 4D flow CMR retrospective valve tracking
(RVT) method (mean difference = −0.08 ml/beat). The
authors suggested that the small difference between 4D
flow CMR and RT3DE may be explained by the fixed
position and the resultant misalignment to the flow direction
of the RT3DE. Another suggestion was that interference
from thoracic obstacles may reduce the accuracy of 3D
echocardiography. In addition to comparing 4D flow CMR and
RT3DE, a comparison of 2D and 3D echocardiography was
conducted. Here the authors observed that 2D echocardiographic
methods of MR quantification remain significantly inferior to
3D echocardiographic methods, systematically underestimating
regurgitant volume (−2.9 ml/beat, p < 0.05). Bland-Altman
analysis of the effective regurgitant orifice area in RT3DE showed
a mean intraobserver bias (±2D) of 0.04 ±0.04 cm2 (p = 0.55)
and a mean interobserver bias (±2D) of 0.06 ±0.4 cm2 (p =
0.43). Other papers have found that traditional methods of TTE
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FIGURE 2 | Literature search flow diagram. Adapted from PRISMA tool (10).
MR quantification are only modestly reliable and, in many cases,
suboptimal (17).
Roes et al. validated 4D flow for flow assessment with all
4 valves simultaneously using retrospective valve tracking. This
was performed for both healthy volunteers and patients with
valvular regurgitation. For regurgitation fraction Roes et al.
found an ICC of 0.86 for intraobserver and 0.85 for interobserver
variation. However, this is a collective statistic for all 4 heart
valves simultaneously, and not solely for MR.
In 2017 Gorodisky et al. published a paper comparing
2D color Doppler TTE with 3-dimensional proximal flow
convergence method of CMR in quantifying MR. The method
used enables the true 3D shape of the PISA to be derived from
the use of 3D velocity gradients. An eccentric shape was found
in almost all cases with a mean eccentricity of 0.81 ± 0.04. The
intraclass correlation coefficient (ICC) of their 4D flow method
for both experienced and inexperienced users was 0.99. Analysis
of the source of bias revealed that this was largely due to the
inexperienced user drawing the region of interest marginally
too large.
In a recent study done by Feneis et al., the investigators
compared 2D PC MRI to 4D flow CMR methods of MR
quantification. They measured the inter technique agreement for
quantifyingMR through direct PC flowmeasurements (Figure 4)
and indirect (LVSV-AoPC) 4D flow analysis and 2D PC. Their
results showed that 2D PC and 4D flow yielded equivalent results
(Pearson correlation 0.902 and 0.819, respectively). Feneis et
al found that interobserver reliability for 4D flow derived MR
ranged from very good to excellent for both direct and indirect
quantification (r = 0.929 and r = 0.877, respectively). For direct
quantification intraobserver analysis of MR flow volume was
excellent for both observers (r = 0.988 and r = 0.986).
In 2018 Kamphuis et al. published a study comparing
automated and manual valve tracking examining; analysis times,
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TABLE 1 | Summary of all studies included in this systematic review.
First author year (Place) N Methods of
quantification
Reproducibility
data
Comparison Main finding
TTE TOE 2D PC
MRI
Westenberg et al. (Leiden)
(10)
30 RVT – – – + 2D PC MRI overestimated mitral valve
flow by 15% in both healthy and MR
patients when compared to 4D flow MRI
Marsan et al. (Leiden) (11) 64 RVT – + – – 4D flow has excellent correlation with
RT3DE whilst TTE significantly
underestimates regurgitant volume
Roes et al. (Leiden) (12) 51 RVT + – – – Intraobserver and interobserver
agreements for 4D flow MV volumes of
0.86 and 0.85 respectively
Brandts et al. (Leiden) (13) 47 RVT – + – + 4D flow found transmitral flow rate to be
lower than 2D PC MRI. There is excellent
agreement between 2D TTE and 4D flow
Gorodisky et al. (Haifa)
(14)
27 CMR - PISA + + – + An eccentric shape was found in almost
all cases by CMR disagreeing with the
hemispheric assumption made in echo
PISA
Feneis et al. (San Diego)
(15)
21 Direct jet
analysis using
4D flow
+ – – + High concordance between 4D flow and
2D PC MRI for both direct and indirect
quantification. Good 4D flow
interobserver and intraobserver reliability
Kamphuis et al. (Leiden)
(16)
160 RVT + – – – Automated valve tracking reduces
analysis times without an increase in
variability
FIGURE 3 | Three-dimensional streamlines visualization of MR (yellow) and
tricuspid regurgitation (blue) using retrospective valve tracking on CAAS
software (Pie Medical Imaging, Maastricht, The Netherlands). In this case, the
MR is mild and there is significant tricuspid regurgitation.
net forward volumes and regurgitant fractions. It was found that
automated valve tracking analysis times were considerably less
than manual times without an increase in variability (14min
[IQR 12–15min] vs. 25min [IQR 20–25min], P < 0.001).
Interestingly, there was disagreement between the two methods
in classification of MR, with the automated method producing
22 discordant cases for MR (k = 0.38, SE = 0.10). Of these
22 cases, 12 cases would have been classified at least mild-to-
moderate regurgitation, potentially changing clinical decisions
and treatment regimens (1). This study demonstrated that
intra- and interobserver variability was improved and variability
reduced when automated valve tracking was compared tomanual
(intraobserver, ICC ≥ 0.99, COV ≤ 5.2%; interobserver, ICC
≥ 0.99, COV ≤ 5.6%). This was seen both in MR patients and
healthy volunteers.
DISCUSSION
The main finding of the evidence synthesized from this
systematic review is that 4D flow derived MR quantification
methods are reproducible and circumvent issues with standard
imaging by both Echocardiography and CMR. As per the
current evidence, quantification of MR is best done by direct
jet quantification using retrospective valve tracking method on
4D flow MRI. The direct jet quantification by RVT is not only
comparable for its accuracy to current standard methods but also
demonstrates greater precision in the papers reviewed.
Comparison Studies to Echocardiography
Echocardiography has long been the standard imaging modality
for assessing MR. It is non-invasive, non-ionizing, and
significantly cheaper and more versatile than CMR or CT
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FIGURE 4 | Direct quantification of an eccentric MR jet using 4D flow MRI data. The mitral valve stroke volume in this case was 110 mls and the regurgitation 80 mls.
The MR fraction was therefore 73% and the net forward flow 5 mls.
techniques (18). Recently, several studies have proven that
standard CMR techniques can quantify MR, mainly by
calculating the difference between left ventricular stroke volume
and aortic forward volume. MR quantified by this CMR method
is better associated with patient outcomes than transthoracic
echocardiography (TTE) (3). However, even standard CMR
has issues in quantifying MR which could be circumvented
by using 4D flow CMR. Three studies included in this
systematic review have compared both 2-dimensional (2D)/3-
dimensional (3D) echocardiography to 4D flow CMR methods
of MR quantification.
Marsan et al. demonstrated that 2D echocardiography
systematically under-estimated MR when compared to RT3DE.
Importantly, RT3DE was comparable to 4D flow method.
However, the RT3DE modality examined by Marsan et al. has
its own limitations when observing MR and quantifying the
regurgitant volume. Firstly, the interobserver reliability of 3D
echocardiography is low for novice users (R = 0.51). Extended
training and practice are therefore required to achieve reliable
quantification of RT3DE measurements (19). There are also
practical limitations of this technique; narrow-angle imaging is
the most suitable for observing mitral valve anatomy, however,
with this view the entire valve is not viewable in one live
3D echocardiography slice. RT3DE is therefore limited by
the stitching artifacts of these slices (20). These artifacts are
often exaggerated in patients with arrhythmias. In addition, the
temporal resolution of RT3DE is reduced, offering ∼25% the
frame rate of its 2D counterpart. This temporal resolution makes
scallop pathologies particularly difficult to detect through this
method and other imaging modalities may need to be relied
upon. In RT3DE several cardiac cycles are often needed to gain
a full analysis of the valve, unlike the 2D echo (21). Some of
these issues are applicable to 4D flow CMR methods as well
and hence future studies need to consider investigating head-on-
comparison between these methods in patients with arrythmias,
especially atrial fibrillation or even high ectopic burden.
Another major limitation of 2D echocardiography highlighted
by Gorodisky et al. is the geometric assumptions that must be
made to quantify MR. The regurgitant jet eccentricity found in
this study disproves the assumption made by color Doppler that
PISA shape is hemispheric. In contrast to 2D color Doppler, 4D
flow takes readings throughout systole and does not assume the
area of regurgitant jet, resulting in a more reliable and accurate
measurement of regurgitation volume.
Transesophageal echocardiography (TOE) offers high-
temporal and spatial resolution in the assessment of MR. This
technique overcomes some of the above-mentioned problems
with TTE, namely, lower spatial resolution and limited views.
Shanks et al. compared both 2D and 3D TOE to CMR in
30 patients with MR. The standard method for quantifying
MR with CMR (LVSV-AoPC) was used. For 3D TOE the
regurgitant volume was calculated by measuring the mitral
effective regurgitant orifice area and multiplying this by the
velocity time integral of the regurgitant jet. The results of this
study showed that 2D TOE again underestimated the regurgitant
volume by 21.6 and 21.3% when compared to 3D TOE and
CMR, respectively. Whereas, 3D TOE demonstrated remarkable
agreement both in regurgitant volume and MR severity grading
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FIGURE 5 | Complementary clinically relevant details can be assessed by using echocardiography; transesophageal echocardiography in this case (blue panel) and
CMR with 4D flow streamline visualization. The MR flow convergence can be better visualized by echocardiography but 4D flow CMR is better to visualize MR jet
within the left atrium. Hence, even though traditional methods of PISA and vena contracta have been proposed for 4D flow CMR, the current best method appears to
be the direct MR jet quantification in the left atrium using the retrospective valve tracking method.
with CMR (22). Several studies have shown that 4D flow is
comparable, if not better than, standard CMR. Therefore, it is
plausible to conclude that 4D flow methods are comparable
to 3D TOE (Figure 5), without the need for a semi-invasive
procedure. In routine clinical practice, 4D flowMRI may be used
in patients where TOE is not suitable as an alternative imaging
modality (23).
The above-mentioned studies collectively demonstrate
the 4D flow quantification methods are comparable to 3D
echocardiographic techniques. With the developments in
4D flow MRI, seen in these papers, methods of accurate
regurgitation volume quantification using CMR have the
potential to be surpass 3D echocardiography.
Comparison Studies to 2D PC MRI
Two-dimensional PC MRI is often the standard against which
4D flow CMR is compared. It is an established technique that
clinically is used for blood flow assessment. Studies from Leiden
have demonstrated that due to through-plane motion during
acquisition, 2D PC tends to overestimate transmitral flow. This
issue is circumvented by using 4D flow MRI which allows to
track the valve plane to generate a dynamic PC plane through the
mitral valve. Importantly, it also allows to track the mitral jet/jets
during systole much more precisely.
It is worth noting that although echocardiography methods
have advanced, some limitations remain, in particular the
fundamental need to be parallel to the ultrasound beam.
The Doppler-derived method for MR quantification used in
Gorodisky’s study typically examines a single frame in systole,
often resulting in a large overestimation of the true regurgitation
volume. The novel three-directional, cross-sectional velocity
CMR-PISA method of quantification proposed in this study
aims to overcome several limitations of other CMR techniques;
including relying on accurate chamber volumes, flow calculations
or assuming all other valves are healthy and that there is no
intracardiac shunt.
Even though Feneis et al. demonstrated that 2D PC
MRI is comparable to 4D flow for MR quantification, the
authors commented that MR jets have the potential to change
shape and direction significantly during systole especially
with primary MR. This will impair measurements taken
within a static imaging plane as in 2D PC MRI. It was
also commented that 4D flow allows for both direct and
indirect quantification without increasing scan time or requiring
physician supervision.
Hence, the current evidence strongly suggests that valve
tracking should be the preferred method for significant through-
plane motion while quantifying MR directly.
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Automated Valve Tracking
A major drawback to the use of 4D flow MRI for MR
quantification is the time-consuming process of manually
tracking the mitral valve in every frame throughout the cardiac
cycle. Automated valve tracking would streamline this process,
decreasing analysis time (16) and improve both intra and
inter-observer variability. However, what is noteworthy from
Kamphuis et al.’s study, is that the automated valve tracking
methods are not completely reliable for MR quantification. This
is likely due to the fact that the MR jet or even jets do not
necessarily follow the valvular plane and need independent
tracking. This makes this procedure complex and further studies
evaluating how this can be improved are warranted.
Reproducibility and Reliability
Intraobserver and interobserver reliability of 4D flow was well-
documented. The most reliable method seen in this systematic
review was from Gorodisky et al.; whilst their 3D CMR-
PISA method is not true 4D flow it did demonstrate excellent
intraclass correlation (ICC = 0.99). Feneis et al. had the most
comprehensive overview of 4D flow methods. Of the tested
methods direct jet quantification with 4D flow was the most
reliable (r = 0.929). Indirect quantification was slightly less
reliable (r = 0.877) but both methods demonstrated high
concordance with 2D PC for MR volume.
Clinical Applications
Current guidelines for the management of MR emphasize the
severity of MR as a key criterion for clinical decision making
(1). This review highlights that current literature supports
the potential use of RVT method to quantify MR (Figure 6).
Other methods including the 4D flow derived PISA methods
demonstrate promising results.
With the advent of accelerated and free-breathing acquisitions
for 4D flow, total scan times have significantly dropped to 8–
10min. In addition, there are now medical software packages
offering RVT or direct flow jet analysis on 4D flow CMR data
(CAAS, Pie Medical Imaging, Maastricht, The Netherlands and
Arterys Cardio, Arterys, San Francisco, CA). This may allow rapid
translation of this technology to benefit the patients. Significant
reduction in analysis times through the use of automated valve
tracking without impairing reliability will aid this translation into
clinical practice. In the near future, 4D flow CMR is not likely
to replace 2D TTE for MR assessment as TTE remains a very
versatile and cheap investigation. However, in patients where
further clarification of MR is needed, 4D flow CMR can provide
FIGURE 6 | (A) A three-chamber cine demonstrating hypointense MR jet in the left atrium. (B) Two-dimensional velocity streamline overlay over the 3-chamber cine
demonstrating flow acceleration of MR. A reconstructed plane (purple dotted line) was used to quantify pulmonary venous flow using 4D flow CMR. (C) Right lateral
pulmonary venous (RLPV) flow demonstrates normal flow pattern (Systolic > Diastolic) with no systolic flow reversal. (D) The direct measure of MR volume using RVT
was 15 mls suggestive of mild MR.
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reliable quantification of MR when compared with 3D TOE. The
direct advantages of using 4D flow CMR over TOE are: it is
completely non-invasive, does not require sedation and hence is a
much more tolerable and safer test for the patients. Additionally,
it can be used in patients with comorbidities that prevent the
TABLE 2 | The strengths and weaknesses of various non-invasive imaging
modalities in the clinical assessment of the mitral valve and MR.
TTE TOE sCMR sCMR + 4D Flow
Etiology of MR ++ +++ + ++
Carpentier classification ++ +++ + +
Number of regurgitant Jets ++ ++ ++ +++
Eccentricity of jet ++ ++ ++ +++
LV volume/function + ++ +++ +++
LA volume + + +++ +++
LV scar + + +++ +++
LV edema – – +++ +++
MR volume
Direct – – + +++
Indirect + ++ +++ +++
4D flow CMR is complementary to TTE, TOE, and standard CMR (sCMR). The addition
of 4D flow to sCMR allows for better direct quantification of MR and visualization of
regurgitant jets.
use of TOE (23). However, 4D flow MRI is not suitable in
all cases and should therefore be used in a complementary
nature to echocardiographic methods. Table 2 is a summarizing
the advantages and disadvantages of the 4 imaging modalities
discussed in this review. There are advantages to both 4D flow
MRI and echocardiographic modalities for the assessment of
MR which confirms that the two methods should be used to
complement each other in clinical practice.
Limitations of 4D Flow
There are many challenges facing adoption of 4D flow CMR.
The current 4D flow CMR workflow requires extensive training
and experience. Till lately, there were no robust software tools
available to quantify flow using 4D flow datasets. Even though
this is changing, the software tools developed by major vendors
need further advancement to make the analysis more intuitive
and simple. One major problem we face is in the development of
understanding of the true “three-dimensional” velocity encoding
visualization vs. one-directional velocity encoding imaging
(echocardiography) which we are so used to. In addition,
current technology prohibits live visualization of 4D flow data
as it requires reconstruction and the hardware vendors do
not have any software packages capable of further analysis.
However, a quick quality check of the data can still be done
slice by slice on each directional dataset on the workstation.
FIGURE 7 | LV volume contours drawn by two different expert users on short-axis cine stack. The left ventricular stroke volume was calculated by both users and
found to be 128 and 147ml, respectively. This difference in calculated stroke volume led to a discrepancy in the classification of this MR case potentially affecting
patient outcomes.
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This includes looking for any breathing, pixilation and aliasing
artifacts in the region of interest. Repeating 4D flow CMR can
be a time-consuming process and hence usually the optimum
velocity (VENC) should be determined using 2D PC acquisition
prior to planning cross-sectional 4D flow CMR. As 4D flow
CMR is essentially a PC acquisition, it can be used for flow
quantification in clinical practice. However, clinical outcome
data demonstrating its non-inferiority to current method are
still warranted.
Future Work
The three-directional, 3D, cross-sectional velocity data acquired
by 4D flow CMR allows quantification of flow and regurgitation
in many novel ways. These methods could include particle
tracing component analysis, intra-cavity energetics (24–26)
RVT to quantify forward and regurgitant jet, 4D flow derived
PISA, semi-quantitative streamline visualization and intra-cavity
hemodynamic forces. The relevance of these methods needs to
be tested and investigated to inform the severity of MR, left
ventricular hemodynamics and predict adverse remodeling. In
addition, it remains unclear which method of MR quantification
is more reliable. Even though the current standard method to
quantify MR by CMR has demonstrated clinical outcome benefit
over echocardiography, its reliability is still debated as slight
changes in contouring LV volumes can result in significant
different MR volume quantification (Figure 7). Future studies
need to prospectively evaluate the clinical outcome benefit of
using 4D flow CMR for MR quantification. In cases of multiple
jets of MR, even RVT segmentation of individual jets, in separate
planes, can be a time-consuming and challenging task. Hence,
novel semi-quantitative and quantitative 4D flow methods are
needed which can simplify the process of MR quantification
without compromising on precision. One promising 4D flow
MRI technique is particle tracing. This requires generating
synthetic particles from the 4D MRI images and tracking these
over the cardiac cycle. The path of these particles can be
visualized as a movie or as a static image of the particle path. It
is yet to be seen if particle tracing can offer benefit other 4D flow
MR quantification methods (27).
CONCLUSION
The evidence gathered in this systematic review suggests that
4D flow derived MR quantification methods are reliable and
circumvent issues with standard imaging. These methods,
namely RVT, offer an alternative imaging modality to quantify
MR in patients with limited acoustic window on TTE or who
need further clarification on the severity of MR. There is a
growing body of evidence demonstrating that 4D flow derived
MR quantification is as accurate as quantified by 3D semi-
invasive TOE. Further studies are warranted to demonstrate
if 4D flow CMR derived MR quantification offers improved
predictability for clinical outcomes over standard imaging.
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